Sonic HealthcareASX:SHL +0.15%82 Net Margin % is 4.82% as of Dec. 2025, which is 44% below its 10-year median of 8.58. GuruFocus rates ASX:SHL with a GF Score™ of 82/100 and a GF Value™ of A$32.93 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Sonic Healthcare ranks better than 64.71% on this metric.
The historical rank and industry rank for Sonic Healthcare's Net Margin % or its related term are showing as below:
ASX:SHL'
s Net Margin % Range Over the Past 10 Years
Min: 5.19 Med: 8.58 Max: 15.67
Current: 5.19
ASX:SHL's Net Margin % is ranked better than 64.71% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs ASX:SHL: 5.19
Sonic Healthcare (ASX:SHL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sonic Healthcare Net Margin % Related Terms
Sonic Healthcare Net Margin % Historical Data
* Premium members only.
The historical data trend for Sonic Healthcare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SHL vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Sonic Healthcare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonic Healthcare Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sonic Healthcare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sonic Healthcare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonic Healthcare (ASX:SHL) has a Net Margin % of 4.82% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sonic Healthcare and its competitors. This is 44% below median its historical median of 8.58. Over the past decade, Sonic Healthcare's Net Margin % has ranged from 5.19 to 15.67. According to the industry distribution chart, Sonic Healthcare ranks #72 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 35.3%.
Is Sonic Healthcare's Net Margin % too high?
Sonic Healthcare's current Net Margin % of 4.82% is 44% below median its 10-year median of 8.58. Over the past 10 years, this metric has ranged from a low of 5.19 to a high of 15.67. Based on the distribution chart, Sonic Healthcare ranks #72 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sonic Healthcare has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonic Healthcare's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sonic Healthcare ranks #72 out of 204 companies for Net Margin %. This puts Sonic Healthcare in the upper half of its industry. Historically, Sonic Healthcare's own Net Margin % has ranged from 5.19 to 15.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sonic Healthcare and its competitors. Sonic Healthcare's current Net Margin % is 4.82%, which is 44% below median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sonic Healthcare (ASX:SHL) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.93, compared to a current price of A$19.86 — trading 39.7% below its estimated fair value. The current Net Margin % is 4.82%, which is 44% below median its 10-year median of 8.58. Sonic Healthcare's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sonic Healthcare (ASX:SHL), the current Net Margin % is 4.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonic Healthcare (ASX:SHL) Overvalued in 2026?
Based on GuruFocus' analysis, Sonic Healthcare stock appears to be undervalued.
The current stock price of A$19.86 is trading 39.7% below its estimated GF Value™ of A$32.93.
GuruFocus considers Sonic Healthcare to be Significantly Undervalued.
Key valuation signals for ASX:SHL:
Net Margin %: 4.82% (44% below median its 10-year median of 8.58)
GF Value™: A$32.93 vs. price of A$19.86 (39.7% below fair value)
No single metric tells the full story. See the ASX:SHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.
82GF Score
Get the complete analysis for ASX:SHL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SHL has been successfully added to your 
